RHOA and prostate cancer: By extending the drug-gene vulnerabilities evaluation beyond the MCF-7 cell line, we discovered that highly potent cancer-killing combinations of SI-12 can also be achieved in triple-negative breast cancer (TNBC), pancreatic, and prostate cancer cells with DNMT and RhoA inhibitors.